This is an observational study designed to follow patients with RA who have had an inadequate response to one or more anti-TNF therapies and who will receive Rituxan. Approximately 1000 patients in the United States with RA who have had an inadequate response to anti-TNF therapies and who will receive Rituxan therapy will be recruited. There is no protocol mandated treatment assignment in this study. Patients will be evaluated and treated according to their physician's standard practice and discretion.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00443443?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
